Show simple item record

dc.contributor.authorSadowska-Bartosz, Izabela
dc.contributor.authorGaliniak, Sabina
dc.contributor.authorBartosz, Grzegorz
dc.contributor.authorRachel, Marta
dc.date.accessioned2016-04-12T08:42:04Z
dc.date.available2016-04-12T08:42:04Z
dc.date.issued2014
dc.identifier.issn1942-0900
dc.identifier.urihttp://hdl.handle.net/11089/17780
dc.description.abstractPseudomonas aeruginosa and Staphylococcus aureus cause chronic lung infection in cystic fibrosis (CF) patients, inducing chronic oxidative stress. Several markers of plasma protein oxidative damage and glycoxidation and activities of erythrocyte antioxidant enzymes have been compared in stable CF patients chronically infected with Pseudomonas aeruginosa (𝑛 = 12) and Staphylococcus aureus (𝑛 = 10) in relation to healthy subjects (𝑛 = 11). Concentration of nitric oxide was also measured in the exhaled air from the lower respiratory tract of patients with CF. Elevated glycophore (4.22 ± 0.91 and 4.19 ± 1.04 versus control 3.18 ± 0.53 fluorescence units (FU)/mg protein; 𝑃 < 0.05) and carbonyl group levels (1.9 ± 0.64, 1.87 ± 0.45 versus control 0.94 ± 0.19 nmol/mg protein; 𝑃 < 0.05) as well as increased glutathione S-transferase activity (2.51 ± 0.88 and 2.57 ± 0.79 U/g Hb versus 0.77 ± 0.16 U/g Hb; 𝑃 < 0.05) were noted in Pseudomonas aeruginosa and Staphylococcus aureus infected CF. Kynurenine level (4.91 ± 1.22 versus 3.89 ± 0.54 FU/mg protein; 𝑃 < 0.05) was elevated only in Staphylococcus aureus infected CF. These results confirm oxidative stress in CF and demonstrate the usefulness of the glycophore level and protein carbonyl groups as markers of oxidative modifications of plasma proteins in this diseasepl_PL
dc.description.sponsorshipThe study has been supported by the Polish Ministry of Science and Higher Education with an Iuventus Plus Grant IP2011047971pl_PL
dc.language.isoenpl_PL
dc.publisherHindawi Publishing Corporationpl_PL
dc.relation.ispartofseriesOxidative Medicine and Cellular Longevity;2014
dc.rightsUznanie autorstwa 3.0 Polska*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/pl/*
dc.titleOxidative Modification of Proteins in Pediatric Cystic Fibrosis with Bacterial Infectionspl_PL
dc.typeArticlepl_PL
dc.page.number1-10pl_PL
dc.contributor.authorAffiliationUniversity of Rzeszów, Department of Biochemistry and Cell Biologypl_PL
dc.contributor.authorAffiliationUniversity of Łódź, Department of Molecular Biophysicspl_PL
dc.contributor.authorAffiliationUniversity of Rzeszów, Faculty of Medicinepl_PL
dc.identifier.eissn1942-0994
dc.referencesJ. B. Lyczak, C. L. Cannon, and G. B. Pier, “Lung infections associated with cystic fibrosis,” Clinical Microbiology Reviews, vol. 15, no. 2, pp. 194–222, 2002pl_PL
dc.referencesJ. F. Chmiel, M. W. Konstan, and J. S. Elborn, “Antibiotic and anti-inflammatory therapies for cystic fibrosis,” Cold Spring Harbor Perspectives in Medicine, vol. 3, no. 10, Article ID a009779, 2013pl_PL
dc.referencesP. J. Dubin and J. K. Kolls, “IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice,” American Journal of Physiology, vol. 292, no. 2, pp. L519–L528, 2007pl_PL
dc.referencesD. E. Geller, “Aerosol antibiotics in cystic fibrosis,” Respiratory Care, vol. 54, no. 5, pp. 658–669, 2009pl_PL
dc.referencesL. R. Usher, R. A. Lawson, I. Geary et al., “Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection,” Journal of Immunology, vol. 168, no. 4, pp. 1861–1868, 2002pl_PL
dc.referencesJ. K. Wong, S. C. Ranganathan, and E. Hart, “Staphylococcus aureus in early cystic fibrosis lung disease,” Pediatric Pulmonology, 2013pl_PL
dc.referencesM. Rottner, S. Tual-Chalot, H. A. Mostefai, R. Andriantsitohaina, J.-M. Freyssinet, and M. C. Martínez, “Increased oxidative stress induces apoptosis in human cystic fibrosis cells,” PLoS ONE, vol. 6, no. 9, Article ID e24880, 2011pl_PL
dc.referencesA. Lezo, F. Biasi, P. Massarenti, et al., “Oxidative stress in stable cystic fibrosis patients: do we need higher antioxidant plasma levels?” Journal of Cystic Fibrosis, vol. 12, pp. 35–41, 2013pl_PL
dc.referencesE. I. Back, C. Frindt, D. Nohr et al., “Antioxidant deficiency in cystic fibrosis: when is the right time to take action?” American Journal of Clinical Nutrition, vol. 80, no. 2, pp. 374–384, 2004pl_PL
dc.referencesI. Sadowska-Woda, M. Rachel, J. Pazdan, E. Bieszczad-Bedrejczuk, and K. Pawliszak, “Nutritional supplement attenuates selected oxidative stress markers in pediatric patients with cystic fibrosis,” Nutrition Research, vol. 31, no. 7, pp. 509–518, 2011pl_PL
dc.referencesR. K. Brown and F. J. Kelly, “Evidence for increased oxidative damage in patients with cystic fibrosis,” Pediatric Research, vol. 36, no. 4, pp. 487–493, 1994pl_PL
dc.referencesM. J. Davies, “The oxidative environment and protein damage,” Biochimica et Biophysica Acta, vol. 1703, no. 2, pp. 93–109, 2005pl_PL
dc.referencesB. Arif, J. M. Ashraf, A. J. Moinuddin, et al., “Structural and immunological characterization of Amadori-rich human serum albumin: role in diabetes mellitus,” Archives of Biochemistry and Biophysics, vol. 522, pp. 17–25, 2012pl_PL
dc.referencesK. Marta, Z. Tomáš, P. Petr et al., “Advanced glycation end-products in patients with chronic alcohol misuse,” Alcohol and Alcoholism, vol. 39, no. 4, pp. 316–320, 2004pl_PL
dc.referencesV. Witko-Sarsat, M. Friedlander, C. Capeillère-Blandin et al., “Advanced oxidation protein products as a novel marker of oxidative stress in uremia,” Kidney International, vol. 49, no. 5, pp. 1304–1313, 1996pl_PL
dc.referencesA. Robaszkiewicz, G. Bartosz, and M. Soszyński, “N-chloroamino acids cause oxidative protein modifications in the erythrocyte membrane,” Mechanisms of Ageing and Development, vol. 129, no. 10, pp. 572–579, 2008pl_PL
dc.referencesM. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44–84, 2007pl_PL
dc.referencesW. H. Habig, M. J. Pabst, and W. B. Jakoby, “Glutathione S transferases. The first enzymatic step in mercapturic acid formation,” Journal of Biological Chemistry, vol. 249, no. 22, pp. 7130–7139, 1974pl_PL
dc.referencesR. A. Dweik, P. B. Boggs, S. C. Erzurum et al., “An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 5, pp. 602–615, 2011pl_PL
dc.referencesNCCLS, “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically,” Approved Standard, 6th Edition. NCCLS document M7-A6, NCCLSpl_PL
dc.referencesA. J. Scott-Thomas, M. Syhre, P. K. Pattemore et al., “2-Aminoacetophenone as a potential breath biomarker for Pseudomonas aeruginosa in the cystic fibrosis lung,” BMC Pulmonary Medicine, vol. 10, article 56, 2010pl_PL
dc.referencesG. A. Tramper-Stranders, T. F. W. Wolfs, A. Fleer, J. L. L. Kimpen, and C. K. Van Der Ent, “Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function,” Pediatric Infectious Disease Journal, vol. 26, no. 1, pp. 8–12, 2007pl_PL
dc.referencesA. Z. Reznick and L. Packer, “Oxidative damage to proteins: spectrophotometric method for carbonyl assay,” Methods in Enzymology, vol. 233, pp. 357–363, 1994pl_PL
dc.referencesT. Henle, R. Deppisch, W. Beck, O. Hergesell, G. M. Hänsch, and E. Ritz, “Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds,” Nephrology Dialysis Transplantation, vol. 14, no. 8, pp. 1968–1975, 1999pl_PL
dc.referencesG. Münch, R. Keis, A. Weßels et al., “Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA1,” European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 35, no. 9, pp. 669–677, 1997pl_PL
dc.referencesO. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951pl_PL
dc.referencesR. N. Johnson, P. A. Metcalf, and J. R. Baker, “Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control,” Clinica Chimica Acta, vol. 127, no. 1, pp. 87–95, 1983pl_PL
dc.referencesR. Mironova, T. Niwa, Y. Handzhiyski, A. Sredovska, and I. Ivanov, “Evidence for non-enzymatic glycosylation of Escherichia coli chromosomal DNA,” Molecular Microbiology, vol. 55, no. 6, pp. 1801–1811, 2005pl_PL
dc.referencesA. T. Diplock, M. C. R. Symons, and C. A. Rice-Evans, Techniques in Free Radical Research, Elsevier Science, Tokyo, Japan, 1991pl_PL
dc.referencesG. L. Ellman, “Tissue sulfhydryl groups,” Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959pl_PL
dc.referencesH. Aebi, “Catalase in vitro,” Methods in Enzymology, vol. 105, pp. 121–126, 1984pl_PL
dc.referencesS. Marklund and G. Marklund, “Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase,” European Journal of Biochemistry, vol. 47, no. 3, pp. 469–474, 1974pl_PL
dc.referencesD. L. Drabkin, “Spectrophotometric studies; the crystallographic and optical properties of the hemoglobin of man in comparison with those of other species,” Journal of Biological Chemistry, vol. 164, pp. 703–723, 1946pl_PL
dc.referencesP. Ø. Jensen, J. Lykkesfeldt, T. Bjarnsholt, H. P. Hougen, N. Høiby, and O. Ciofu, “Poor antioxidant status exacerbates oxidative stress and inflammatory response to Pseudomonas aeruginosa lung infection in guinea pigs,” Basic and Clinical Pharmacology and Toxicology, vol. 110, no. 4, pp. 353–358, 2012pl_PL
dc.referencesO. Ciofu, B. Riis, T. Pressler, H. E. Poulsen, and N. Høiby, “Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 6, pp. 2276–2282, 2005pl_PL
dc.referencesB. M. Winklhofer-Roob, “Oxygen free radicals and antioxidants in cystic fibrosis: the concept of an oxidant-antioxidant imbalance,” Acta Paediatrica, vol. 83, no. 395, pp. 49–57, 1994pl_PL
dc.referencesF. Galli, A. Battistoni, R. Gambari et al., “Oxidative stress and antioxidant therapy in cystic fibrosis,” Biochimica et Biophysica Acta, vol. 1822, no. 5, pp. 690–713, 2012pl_PL
dc.referencesR. K. Brown, H. Wyatt, J. F. Price, and F. J. Kelly, “Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress,” European Respiratory Journal, vol. 9, no. 2, pp. 334–339, 1996pl_PL
dc.referencesC. C. Winterbourn, M. J. D. Bonham, H. Buss, F. M. Abu-Zidan, and J. A. Windsor, “Elevated protein carbonyls as plasma markers of oxidative stress in acute pancreatitis,” Pancreatology, vol. 3, no. 5, pp. 375–382, 2003pl_PL
dc.referencesM.-N. Feuillet-Fieux, T. Nguyen-Khoa, M.-A. Loriot et al., “Glutathione S-transferases related to P. aeruginosa lung infection in cystic fibrosis children: preliminary study,” Clinical Biochemistry, vol. 42, no. 1-2, pp. 57–63, 2009pl_PL
dc.referencesT. Satoh, S. R. McKercher, and S. A. Lipton, “Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs,” Free Radical Biology and Medicine, vol. 65, pp. 645–657, 2013pl_PL
dc.referencesY. Xu, C. Duan, Z. Kuang, et al., “Pseudomonas aeruginosa pyocyanin activates Nrf2-ARE-mediated transcriptional response via the ROS-EGFR-PI3K-AKT/MEK-ERK MAP kinase signaling in pulmonary epithelial cells,” PLoS ONE, vol. 8, Article ID e72528, 2013pl_PL
dc.referencesR. K. Michl, J. Hentschel, C. Fischer, et al., “Reduced nasal nitric oxide production in cystic fibrosis patients with elevated systemic inflammation markers,” PLoS ONE, vol. 8, Article ID e79141, 2013pl_PL
dc.referencesL. Fila, J. Chladek, M. Maly, et al., “Nitrites and nitrates in exhaled breath condensate in cystic fibrosis: relation to clinical parameters,” Bratislavske Lekarske Listy, vol. 114, pp. 503–507, 2013pl_PL
dc.referencesS. R. Thomas, S. A. Kharitonov, S. F. Scott, M. E. Hodson, and P. J. Barnes, “Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype,” Chest, vol. 117, no. 4, pp. 1085–1089, 2000pl_PL
dc.referencesC. M. Robroeks, P. P. R. Rosias, D. van Vliet et al., “Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children,” Pediatric Allergy and Immunology, vol. 19, no. 7, pp. 652–659, 2008pl_PL
dc.referencesK. M. de Winter-de Groot, S. van Haren Noman, L. Speleman, et al., “Nasal nitric oxide levels and nasal polyposis in children and adolescents with cystic fibrosis,” JAMA Otolaryngology, vol. 139, pp. 931–936, 2013pl_PL
dc.referencesM. Zhou, Y. Liu, and Y. Duan, “Breath biomarkers in diagnosis of pulmonary diseases,” Clinica Chimica Acta, vol. 413, pp. 1770–1780, 2012pl_PL
dc.referencesL. P. Ho, J. A. Innes, and A. R. Greening, “Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis,” European Respiratory Journal, vol. 12, no. 6, pp. 1290–1294, 1998pl_PL
dc.referencesW. T. Walker, A. Liew, A. Harris, et al., “Upper and lower airway nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and asthma,” Respiratory Medicine, vol. 107, pp. 380–386, 2013pl_PL
dc.contributor.authorEmailisadowska@poczta.fmpl_PL
dc.identifier.doi10.1155/2014/389629


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Uznanie autorstwa 3.0 Polska
Except where otherwise noted, this item's license is described as Uznanie autorstwa 3.0 Polska